



#10
Doct.
6/16/99
Patent

Attorney's Docket No. 012627-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Hanswalter ZENTGRAF et al)	Group Art Unit: 1627
)	
Serial No.: 08/973,815)	Examiner: S. Priebe
)	
Filed: April 3, 1998)	ATTENTION: BOX SEQUENCE
)	
For: DNASE-ACTIVE PROTEIN)	

DECLARATION PURSUANT TO
37 C.F.R. §§1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Teresa Stanek Rea, declare as follows:


1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
2. That the submission, filed in accordance with 37 C.F.R. §1.821(g)[or (h)], herein does not include new matter [or go beyond the disclosure in the international application].
3. That the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), is identical to that originally filed.

Serial No.: 08/973,815

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

10 June 1998



Teresa Stanek Rea
Registration No. 30,427

To Murthy Date 6/16/99

SPE, Art Unit 1652

The following application has been originally assigned to Art Unit 1632/1633.

In cases where the bulk of the claimed invention was drawn to subject matter that would be assigned to another Art Unit, Post-classification reviewed the application to identify that alternative Art Unit. Please review the attached application and decide if you will accept it at this time.

If you accept the application, the following claims have been identified as being drawn to subject matter that needs to be restricted. Should applicant elect to pursue this subject matter, please return/transfer the application back to Art Unit 1632/1633.

Thank you for your help.

Brian Stanton
SPE, Art Unit 1632

Claims to be restricted out.

Claim(s)	Subject Matter	Classification
<u>11 (in part)</u>	<u>Gene Therapy</u>	<u>514/44</u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>

Note: PCT Zach of Unity applies. Claim 1 is so broad that it encompasses any DNase that shares at least 1 amino acid (a fragment) of the DNase of Fig. 1. ^{eg} ~~any~~ has an alanine. For Zach of Unity, cite reference showing ^{any} DNase, say EcoRI for example, & hold Zach of Unity & split @ product & method into separate groups (or any other way you want to group claims). Cl. 11 & 12 each embrace 3 distinct methods.

Scott Priele
1632